David Hsi, MD
Cardiovascular Disease · Stamford, CTNPI 1588616312
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $3,384 of the $4,846 with a category attached, or 69.8%. Edwards Lifesciences accounts for 70.2% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $3,681 and has fallen 87.0% since, to $477 in 2025.
Across 24 payments — averaging $201.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$3K
- Abbott$548
- E.r. Squibb & Sons, L.L.C.$281
- Bridgebio Pharma, Inc.$149
- Silk Road Medical, Inc.$120
- Esperion Therapeutics, Inc.$111
- plus $234 from 8 others
Across 29 payments — averaging $1363.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$21K
- Abbott$14K
- American Regent$3K
- Recor Medical Inc$2K
What the payments were for
- Travel & lodging$3,38470%
- Food & beverage$1,46230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 2 | $3,404 |
| Abbott | 5 | $548 |
| E.r. Squibb & Sons, L.L.C. | 3 | $281 |
| Bridgebio Pharma, Inc. | 1 | $149 |
| Silk Road Medical, Inc. | 1 | $120 |
| Esperion Therapeutics, Inc. | 1 | $111 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $85 |
| Novartis | 1 | $32 |
| Preventice Services, LLC | 1 | $23 |
| Irhythm Technologies, Inc. | 1 | $23 |
| Siemens Medical Solutions USA, Inc. | 1 | $22 |
| Merck | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,846 in reported general payments places this provider in the 75th percentile of 415 cardiovascular disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 156 | $208,775 |
| XareltoRivaroxaban | 36 | $50,547 |
| EntrestoSacubitril/Valsartan | 14 | $26,524 |
| JardianceEmpagliflozin | 13 | $20,878 |
| NexlizetBempedoic Acid/Ezetimibe | 21 | $12,582 |
| NexletolBempedoic Acid | 19 | $9,427 |
| Atorvastatin Calcium | 317 | $3,010 |
| Metoprolol Succinate | 306 | $2,912 |
| Ranolazine ErRanolazine | 15 | $2,140 |
| Valsartan | 97 | $1,972 |
| Rosuvastatin Calcium | 182 | $1,897 |
| Losartan Potassium | 221 | $1,859 |
| Amlodipine Besylate | 321 | $1,818 |
| Carvedilol | 192 | $1,190 |
| Nifedipine ErNifedipine | 16 | $1,114 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $15 | $208,775156 claims |
| NovartisEntresto | $32 | $26,52414 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $111 | $22,00940 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 415 cardiovascular disease providers in Connecticut.
Other cardiovascular disease in Stamford
- Jeffrey GreenStamford$15K
- Nihar DesaiNew Haven$1.4M
- Brett NowlanBloomfield$798K
- Jeffery TestaniNew Haven$546K
- Carlos Mena-HurtadoNew Haven$460K
- Stephanie SaucierHartford$243K
- John ForrestNew Haven$164K
- Henry WardNew Haven$152K
- Ricardo CordidoHamden$135K
- Antonio FernandezHartford$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.